诺和诺德的口服减肥药 Amycretin，在 1 期试验中显示出 10.4-13.4% 的体重减轻，优于安慰剂。 Novo Nordisk's oral weight loss pill, Amycretin, demonstrated 10.4-13.4% body weight loss in phase 1 trials, outperforming placebo.

诺和诺德的口服减肥药 Amycretin 在早期试验中显示出令人鼓舞的结果。 Novo Nordisk's oral weight loss pill, Amycretin, has shown encouraging results in early trials. 在一项 1 期研究中，参与者在 12 周内在最低剂量下减轻了 10.4% 的体重，在较高剂量下减轻了 13% 以上，而安慰剂组的参与者仅减轻了 1%。 In a phase 1 study, participants lost 10.4% of their body weight at the lowest dose and over 13% at a higher dose over 12 weeks, compared to just 1% for those on a placebo. Amycretin 靶向 GLP-1 和胰岛淀粉样肽激素受体，类似于现有的注射减肥药。 Amycretin targets GLP-1 and amylin hormone receptors, similar to existing injectable weight loss drugs.